Suresh Ramalingam, MD, FACP, FASCO, a professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine, is the executive director of the Winship Cancer Institute and associate vice president for cancer, Woodruff Health Sciences Center, Atlanta, Georgia. Ramalingham spoke with The American Journal of Managed Care® (AJMC®) about the current treatment and research landscape involving EGFR Exon 20 insertion+ NSCLC.
Read More
EP. 4: Roy Beveridge, MD, Discusses Pathways, NCCN Guidelines in EGFR Exon 20 Insertion+ NSCLC
October 12th 2022Beveridge, now with Avalere Health, addressed the importance of clinical pathways in selecting therapies in non-small cell lung cancer (NSCLC) and the emergence of options for EGFR Exon 20 Insertion+ NCSLC.
Read More
EP. 5: Dr Joshua Sabari: “Tissue Is the Issue” in NGS for EGFR Exon 20 Insertion+ NSCLC
November 17th 2022Joshua Sabari, MD, assistant professor of medicine, Medical Oncology, Perlmutter Cancer Center at NYU Langone Health, New York, New York, discusses topics involving next generation sequencing (NGS) to develop molecular profiles in the treatment of non-small cell lung cancer (NSCLC).
Read More